{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:56:36Z","timestamp":1765486596375,"version":"3.40.5"},"reference-count":24,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,12]]},"abstract":"Aims<\/jats:title>Raxibacumab is a fully humanized monoclonal antibody that blocks the interaction of Bacillus anthracis<\/jats:italic><\/jats:styled-content> toxins, thereby protecting target cells from its effects. Raxibacumab is approved in the USA for the treatment of adults and children with inhalational anthrax in combination with antibiotics, and for prophylaxis of inhalational anthrax. The aim of this investigation was to characterise the population pharmacokinetics and assess the effect of baseline demographic covariates on the disposition of raxibacumab.<\/jats:p><\/jats:sec>Methods<\/jats:title>The data used for this analysis were obtained from 3 clinical trials and include 2229 blood samples from 322 healthy subjects who were randomised to receive a 40\u2009mg\/kg intravenous dose of raxibacumab over a period of 2.25\u2009hours. Population pharmacokinetic modelling was performed using a nonlinear mixed effects approach. Secondary parameters of interest were the area under the curve, maximum concentration and the time of serum raxibacumab concentrations greater than or equimolar to the highest serum protective antigen concentrations observed for at least 28\u2009days in any monkey challenged with B. anthracis<\/jats:italic><\/jats:styled-content> that died.<\/jats:p><\/jats:sec>Results<\/jats:title>Raxibacumab exposure in healthy subjects was described by a 2\u2010compartment model. Interindividual variability was estimated for all model parameters, whilst residual variability was described by a proportional and additive error model. Weight was the only influential covariate with significant effect on disposition parameters.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>A dose of 40\u2009mg\/kg provided comparable exposure across the overall healthy subject population. Interindividual variability in raxibacumab vs<\/jats:italic>. time profiles could partially be accounted for by differences in body weight.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.14894","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T16:27:58Z","timestamp":1620750478000},"page":"4718-4725","source":"Crossref","is-referenced-by-count":2,"title":["Population pharmacokinetics of raxibacumab in healthy adult subjects"],"prefix":"10.1111","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4346-0088","authenticated-orcid":false,"given":"Sean P.","family":"Oosterholt","sequence":"first","affiliation":[{"name":"Clinical Pharmacology & Therapeutics Group University College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6211-1430","authenticated-orcid":false,"given":"Oscar","family":"Della Pasqua","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology & Therapeutics Group University College London London UK"},{"name":"Clinical Pharmacology Modelling and Simulation GlaxoSmithKline Brentford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-4-200602210-00009"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7973702"},{"key":"e_1_2_10_4_1","unstructured":"US Department of Justice.Amerithrax investigative summary 2010. Available at:https:\/\/www.justice.gov\/archive\/amerithrax\/docs\/amx-investigative-summary.pdf(last accessed on 05\/11\/20)."},{"key":"e_1_2_10_5_1","unstructured":"Centers for Disease Control and Prevention.Anthrax symptoms. Available at:https:\/\/www.cdc.gov\/anthrax\/basics\/symptoms.html(last accessed on 05\/11\/20)."},{"key":"e_1_2_10_6_1","unstructured":"The National Institute for Health and Care Excellence (NICE).Anthrax 2019. Available at:https:\/\/bnf.nice.org.uk\/treatment-summary\/anthrax.html(last accessed on 05\/11\/20)."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2005.11.035"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.17.2236"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid0706.010604"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.07.105"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1086\/430708"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2003.09.003"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810603"},{"key":"e_1_2_10_14_1","unstructured":"U.S. drug label. Raxibacumab (2018 rev.) 2018. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125349s022lbl.pdf(last accessed on 05\/11\/20)."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04606-14"},{"volume-title":"R: A Language and Environment for Statistical Computing","year":"2015","author":"R Core Team","key":"e_1_2_10_16_1"},{"key":"e_1_2_10_17_1","doi-asserted-by":"crossref","unstructured":"HendricksKA WrightME ShadomySV et al.Centers for Disease Control and Prevention Expert Meetings on Prevention and Treatment of Anthrax in Adults 2014. Available at:https:\/\/wwwnc.cdc.gov\/eid\/article\/20\/2\/13-0687_article(last accessed on 05\/11\/20).","DOI":"10.3201\/eid2002.130687"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S47305"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.1.13799"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1081"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30069-4"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0577-0"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.07.170"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0974-3"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06446-11"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14894","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14894","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T04:56:14Z","timestamp":1693198574000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1111\/bcp.14894"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14894","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2021,7,14]]}}}